Structure Therapeutics
GPCR
172 hedge funds and large institutions have $1.13B invested in Structure Therapeutics in 2025 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 63 increasing their positions, 43 reducing their positions, and 16 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
138% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 16
62.8% more ownership
Funds ownership: 32.51% → 95.31% (+63%)
47% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 43
18% more call options, than puts
Call options by funds: $12.5M | Put options by funds: $10.5M
16% more capital invested
Capital invested by funds: $981M → $1.13B (+$153M)
15% more funds holding
Funds holding: 150 → 172 (+22)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$47.2M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$22.7M |
| 3 |
O
OrbiMed
New York
|
+$12M |
| 4 |
CC
Casdin Capital
New York
|
+$11.5M |
| 5 |
PHAM
Pacific Heights Asset Management
San Francisco,
California
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$37.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$21.3M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$20.1M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$19.9M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$15.4M |
GPCR Hedge Fund Activity: Q2 2025 in Review
172 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Structure Therapeutics (GPCR) for Q2 2025, worth a combined $1.13B — up 16% from $981M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new GPCR positions and 16 closed out — a net gain of 22 holders — while 63 added to existing stakes and 43 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $47.2M. The largest seller was Capital Research Global Investors, exiting entirely with an estimated $37.5M sold.
- 172 institutional investors held Structure Therapeutics (GPCR) as of Q2 2025, up from 150 in Q1 2025.
- Funds reported $1.13B of Structure Therapeutics stock for Q2 2025, up 16% quarter-over-quarter.
- 38 funds opened new Structure Therapeutics positions in Q2 2025 and 16 closed out, a net change of +22 holders.
- The largest Structure Therapeutics buyer in Q2 2025 was Baker Bros. Advisors, an estimated $47.2M added.
- The largest Structure Therapeutics seller in Q2 2025 was Capital Research Global Investors, an estimated $37.5M sold.
Based on aggregated 13F filings for Q2 2025.